Status:
COMPLETED
Modulating Impulsivity in Suicidal Adolescents With Transcranial Direct Current Stimulation (tDCS)
Lead Sponsor:
Lifespan
Conditions:
Impulsive Behavior
Eligibility:
All Genders
13-17 years
Phase:
NA
Brief Summary
As a first step toward investigating whether modulation of impulsivity and associated neural pathways may yield clinically meaningful changes in risk for adolescent suicidal behavior, the R21 is a pro...
Detailed Description
Suicide is one of the leading causes of death in adolescence. To improve the ability to predict and prevent suicidal behavior, there is a pressing need for research in this area to advance beyond iden...
Eligibility Criteria
Inclusion
- have attempted suicide prior to admission
- speak and read English fluently
- do not display evidence of significant cognitive impairment, based on a standard psychiatric exam as well as school records on admission
- are not actively psychotic at time of intake.
Exclusion
- a significant general medical condition
- history of seizure, head injury, brain surgery or tumor
- intracranial metallic implants or implanted electrical devices
- substance abuse or dependence in the past six months.
Key Trial Info
Start Date :
April 1 2017
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 31 2019
Estimated Enrollment :
64 Patients enrolled
Trial Details
Trial ID
NCT03365102
Start Date
April 1 2017
End Date
December 31 2019
Last Update
February 2 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Bradley Hospital
Riverside, Rhode Island, United States, 02915